Colorectal Cancer Therapeutics companies

  • Report ID: 436
  • Published Date: Aug 22, 2025
  • Report Format: PDF, PPT

Key Colorectal Cancer Therapeutics Market Players:

    The market hosts an intensifying landscape with giants such as Roche, Merck, and Bristol-Myers Squibb dominating with the presence of immunotherapies and targeted drugs. Besides the U.S. and Europe-based players lead in terms of checkpoint inhibitors, whereas emerging economies such as India and South Korea contribute biosimilars at an affordable cost. Further, the strategic collaborations opted for by Chugai and Roche shape innovation in this sector.

    Here is the list of some prominent players in the industry:

    Company Name

    Country

    Market Share (2024)

    Industry Focus

    Roche

    Switzerland

    26.2%

    Leader in Bevacizumab (Avastin) and targeted therapies.

    Merck & Co.

    U.S.

    19.3%

    Pembrolizumab (Keytruda) for metastatic CRC.

    Bristol-Myers Squibb

    U.S.

    13.1%

    Nivolumab (Opdivo) for immunotherapy.

    Amgen

    U.S.

    11.8%

    Panitumumab (Vectibix) and biosimilars.

    Pfizer

    U.S.

    10.1%

    Chemotherapy drugs like Capecitabine (Xeloda).

    Novartis

    Switzerland

    xx%

    Targeted therapy with Zoledronic Acid (Zometa).

    Sanofi

    France

    xx%

    Irinotecan (Camptosar) for chemotherapy.

    AstraZeneca

    UK/Sweden

    xx%

    Developing Olaparib (Lynparza) for CRC.

    Eli Lilly

    U.S.

    xx%

    Ramucirumab (Cyramza) for advanced CRC.

    Bayer

    Germany

    xx%

    Regorafenib (Stivarga) for refractory CRC.

    Johnson & Johnson

    U.S.

    xx%

    Exploring immunotherapies for CRC.

    GSK (GlaxoSmithKline)

    UK

    xx%

    Researching PARP inhibitors for CRC.

    Celltrion

    South Korea

    xx%

    Biosimilars for CRC treatments.

    Biocon

    India

    xx%

    Affordable biosimilars in emerging markets.

    Takeda Pharmaceutical

    Japan

    xx%

    Expanding in biologics and combination therapies.

    Daiichi Sankyo

    Japan

    xx%

    Trifluridine/Tipiracil (Lonsurf) for metastatic CRC.

    Astellas Pharma

    Japan

    xx%

    Focus on precision oncology and targeted drugs.

    Otsuka Pharmaceutical

    Japan

    xx%

    Exploring novel CRC therapies in clinical trials.

    Eisai Co.

    Japan

    xx%

    Lenvatinib (Lenvima) is under investigation for CRC.

    Chugai Pharmaceutical

    Japan

    xx%

    Partner with Roche, specializing in biologics & diagnostics.

    Below are the areas covered for each company under the top global manufacturers:

    • Company Overview 
    • Business Strategy 
    • Key Product Offerings 
    • Financial Performance 
    • Key Performance Indicators 
    • Risk Analysis 
    • Recent Development 
    • Regional Presence 
    • SWOT Analysis

Browse key industry insights with market data tables & charts from the report:

Frequently Asked Questions (FAQ)

In the year 2026, the industry size of the colorectal cancer therapeutics market was over USD 14.2 billion.

The market size for the colorectal cancer therapeutics market is projected to reach USD 21.7 billion by the end of 2035, expanding at a CAGR of 4.8% during the forecast period, i.e., between 2026-2035.

The major players in the market are Roche, Merck & Co., Bristol-Myers Squibb, Amgen, and others.

In terms of the cancer stage segment, the metacystic stage segment is anticipated to garner the largest market share of 4.8%% by 2035 and display lucrative growth opportunities during 2026-2035.

The market in North America is projected to hold the largest market share of 42.7% by the end of 2035 and provide more business opportunities in the future.
Inquiry Before Buying Request Free Sample PDF
footer-bottom-logos